Sarepta Therapeutics | SRPT - Pre Tax Profit


Sarepta Therapeutics reported $343.17M in Pre-Tax Profit for its fiscal quarter ending in March of 2026.





Pre Tax Profit Change Date
Acadia Pharmaceuticals USD 3.98M 22.34M Mar/2026
Agios Pharmaceuticals USD -99.11M 9.94M Mar/2026
Alnylam Pharmaceuticals USD 221.65M 60.52M Mar/2026
Amgen USD 1.51B 2.41B Dec/2025
BioCryst Pharmaceuticals USD 248.02M 235.89M Dec/2025
Biogen USD 377.7M 433.7M Mar/2026
BioMarin Pharmaceutical USD 141.2M 168.36M Mar/2026
Capricor Therapeutics USD -30.17M 5.6M Dec/2025
Daiichi Sankyo JPY 106.73B 48.96B Dec/2025
Eli Lilly USD 8.27B 1.03B Dec/2025
Esperion Therapeutics USD 63.67M 95M Dec/2025
Gilead Sciences USD 2.08B 1.56B Dec/2025
Incyte USD 343.6M 46.34M Mar/2026
Insmed USD -162.1M 164.84M Mar/2026
Ionis Pharmaceuticals USD -93M 135M Mar/2026
Moderna USD -799M 612M Dec/2025
Nektar Therapeutics USD -34.7M 2.35M Dec/2025
Neurocrine Biosciences USD 246.8M 7.4M Mar/2026
Novavax USD 17.9M 220.94M Dec/2025
Pfizer USD 5.18B 6.82B Mar/2026
PTC Therapeutics USD -2.46M 136.62M Mar/2026
Regeneron Pharmaceuticals USD 1.04B 719.6M Dec/2025
Roche Holding CHF 4.79B 3.01B Jun/2025
Sangamo BioSciences USD -36.05M 12.94M Jun/2024
Sanofi EUR -1.16B 5.5B Dec/2025
Sarepta Therapeutics USD 343.17M 750.85M Mar/2026
Tectonic Therapeutic USD -18.97M 63K Dec/2025
Ultragenyx Pharmaceutical USD -184M 56M Mar/2026
Vertex Pharmaceuticals USD 1.25B 78.1M Mar/2026